

Ranjana H Advani

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3936977/ranjana-h-advani-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|---------------|-----------------|
| 219 papers | 16,927 citations | 53 h-index | 129 g-index |
| 224 ext. papers | 20,623 ext. citations | 5 avg, IF | 6.24 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 219 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016 , 127, 2375-90 | 2.2 | 4080 |
| 218 | Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2013 , 369, 507-16 | 59.2 | 1139 |
| 217 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2013 , 31, 88-94 | 2.2 | 858 |
| 216 | Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2190-6 | 2.2 | 759 |
| 215 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015 , 21, 922-6 | 50.5 | 707 |
| 214 | Ibrutinib in previously treated Waldenström's macroglobulinemia. <i>New England Journal of Medicine</i> , 2015 , 372, 1430-40 | 59.2 | 617 |
| 213 | PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2690-7 | 2.2 | 472 |
| 212 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 1711-1721 | 59.2 | 456 |
| 211 | Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. <i>New England Journal of Medicine</i> , 2013 , 368, 1408-16 | 59.2 | 388 |
| 210 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240 | 40 | 283 |
| 209 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015 , 126, 739-45 | 2.2 | 268 |
| 208 | Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016 , 128, 2489-2496 | 2.2 | 235 |
| 207 | Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016 , 8, 364ra155 | 17.5 | 231 |
| 206 | Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014 , 123, 3095-100 | 2.2 | 224 |
| 205 | Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013 , 31, 684-91 | 2.2 | 204 |
| 204 | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 1183-1194 | 2.2 | 203 |
| 203 | A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. <i>Clinical Cancer Research</i> , 2012 , 18, 248-55 | 12.9 | 190 |

| | | | |
|-----|--|------|-----|
| 202 | Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3750-8 | 2.2 | 186 |
| 201 | Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015 , 125, 1394-402 | 2.2 | 185 |
| 200 | Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1454-9 | 2.2 | 182 |
| 199 | Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2845-2853 | 2.2 | 164 |
| 198 | Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012 , 120, 3280-7 | 2.2 | 159 |
| 197 | Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4371-7 | 2.2 | 158 |
| 196 | Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 692-700 | 2.2 | 145 |
| 195 | Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 120, 560-8 | 2.2 | 140 |
| 194 | Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018 , 132, 40-48 | 2.2 | 132 |
| 193 | A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 168, 811-9 | 4.5 | 131 |
| 192 | Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3137-43 | 2.2 | 127 |
| 191 | Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016 , 128, 1321-8 | 2.2 | 125 |
| 190 | Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017 , 130, 2709-2717 | 2.2 | 121 |
| 189 | Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 24 | 22.4 | 119 |
| 188 | Classical Hodgkin Lymphoma with Reduced M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016 , 4, 910-916 | 12.5 | 118 |
| 187 | MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011 , 17, 4125-35 | 12.9 | 110 |
| 186 | Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019 , 6, e254-e265 | 14.6 | 108 |
| 185 | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013 , 121, 3547-53 | 2.2 | 102 |

| | | | |
|-----|--|------|----|
| 184 | Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 172, 735-44 | 4.5 | 88 |
| 183 | Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017 , 129, 2519-2525 | 2.2 | 87 |
| 182 | The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013 , 161, 76-86 | 4.5 | 86 |
| 181 | Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. <i>Blood</i> , 2013 , 121, 745-51 | 2.2 | 84 |
| 180 | Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 912-8 | 2.2 | 82 |
| 179 | NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1067-79 | 7.3 | 80 |
| 178 | Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3119-26 | 2.2 | 75 |
| 177 | Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3359-3368 | 2.2 | 71 |
| 176 | Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015 , 170, 669-78 | 4.5 | 69 |
| 175 | Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. <i>Leukemia and Lymphoma</i> , 2007 , 48, 521-5 | 1.9 | 64 |
| 174 | Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. <i>Clinical Cancer Research</i> , 2018 , 24, 4110-4118 | 12.9 | 60 |
| 173 | A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 44 | 22.4 | 59 |
| 172 | Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3015-3022 | 2.2 | 57 |
| 171 | A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. <i>Cancer</i> , 2004 , 100, 321-6 | 6.4 | 56 |
| 170 | A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. <i>British Journal of Haematology</i> , 2016 , 172, 535-44 | 4.5 | 56 |
| 169 | A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1373-9 | 1.9 | 55 |
| 168 | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014 , 165, 358-63 | 4.5 | 54 |
| 167 | Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742 | 2.2 | 54 |

| | | | |
|-----|--|------|----|
| 166 | Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015 , 90, 778-83 | 7.1 | 53 |
| 165 | Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 1167-1176 | 12.9 | 50 |
| 164 | First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018 , 9, 13023-13035 | 3.3 | 45 |
| 163 | Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 111-21 | 3.5 | 44 |
| 162 | Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. <i>Therapeutic Advances in Hematology</i> , 2014 , 5, 121-33 | 5.7 | 44 |
| 161 | Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020 , 7, e827-e837 | 14.6 | 44 |
| 160 | The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019 , 125, 1507-1517 | 6.4 | 42 |
| 159 | Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021 , 39, 565-575 | 2.2 | 40 |
| 158 | Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018 , 131, 2120-2124 | 2.2 | 39 |
| 157 | Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015 , 170, 56-65 | 4.5 | 38 |
| 156 | How I treat nodular lymphocyte predominant Hodgkin lymphoma. <i>Blood</i> , 2013 , 122, 4182-8 | 2.2 | 37 |
| 155 | Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. <i>Clinical Cancer Research</i> , 2010 , 16, 2167-75 | 12.9 | 36 |
| 154 | Brentuximab vedotin in transplant-naïve patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. <i>Oncologist</i> , 2012 , 17, 1073-80 | 5.7 | 36 |
| 153 | Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1607-1616 | 1.9 | 35 |
| 152 | Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. <i>British Journal of Haematology</i> , 2018 , 180, 164-166 | 4.5 | 34 |
| 151 | Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018 , 124, 136-144 | 6.4 | 34 |
| 150 | A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. <i>Cancer</i> , 2017 , 123, 1174-1183 | 6.4 | 33 |
| 149 | Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015 , 33, 740-8 | 2.2 | 30 |

| | | | |
|-----|---|------|----|
| 148 | Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. <i>Radiology</i> , 2016 , 280, 220-9 | 20.5 | 30 |
| 147 | A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013 , 122, 251-251 | 2.2 | 29 |
| 146 | Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. <i>Blood</i> , 2015 , 126, 470-470 | 2.2 | 27 |
| 145 | Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021 , 138, 427-438 | 2.2 | 27 |
| 144 | Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018 , 181, 760-769 | 4.5 | 26 |
| 143 | Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2568-2578 | 1.9 | 26 |
| 142 | Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 703-10 | 1.9 | 25 |
| 141 | The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1100-1118 | 4 | 25 |
| 140 | A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 848-848 | 2.2 | 25 |
| 139 | Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1936-42 | 2.2 | 24 |
| 138 | A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 182-182 | 2.2 | 24 |
| 137 | Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015 , 126, 585-585 | 2.2 | 23 |
| 136 | How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. <i>Molecular Imaging and Biology</i> , 2018 , 20, 324-335 | 3.8 | 22 |
| 135 | Ibrutinib in Waldenström's macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 179-86 | 5.7 | 22 |
| 134 | Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. <i>Leukemia and Lymphoma</i> , 2012 , 53, 718-20 | 1.9 | 22 |
| 133 | Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e410-e421 | 14.6 | 20 |
| 132 | Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1718-1726 | 12.9 | 20 |
| 131 | Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020 , 95, 151-155 | 7.1 | 19 |

| | | | |
|-----|--|------|----|
| 130 | Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 193-200 | 2 | 18 |
| 129 | Speeding up PET/MR for cancer staging of children and young adults. <i>European Radiology</i> , 2016 , 26, 4238-4248 | 3.1 | 17 |
| 128 | Optimal therapy of advanced Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011 , 2011, 310-6 | 2.2 | 16 |
| 127 | Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016 , 128, 621-621 | 2.2 | 16 |
| 126 | Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020 , 4, 253-262 | 7.8 | 16 |
| 125 | Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin Disease: Mature Data in Early and Advanced Stage Patients.. <i>Blood</i> , 2004 , 104, 308-308 | 2.2 | 15 |
| 124 | Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1105-1105 | 2.2 | 15 |
| 123 | The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021 , 39, 1422-1437.e10 | 24.3 | 15 |
| 122 | SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma: Evidence of Antitumor Activity from a Phase I Study.. <i>Blood</i> , 2006 , 108, 695-695 | 2.2 | 14 |
| 121 | Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019 , 134, 238-238 | 2.2 | 13 |
| 120 | Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2014 , 124, 1741-1741 | 2.2 | 13 |
| 119 | Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3095-3095 | 2.2 | 13 |
| 118 | Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. <i>Haematologica</i> , 2018 , 103, e466-e468 | 6.6 | 13 |
| 117 | Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 99-106 | 4 | 12 |
| 116 | A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018 , 132, 679-679 | 2.2 | 12 |
| 115 | The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , 2011 , 118, 442-442 | 2.2 | 12 |
| 114 | Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. <i>Blood</i> , 2012 , 120, 797-797 | 2.2 | 12 |
| 113 | A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 604-8 | 1.9 | 11 |

| | | | |
|-----|---|-----|----|
| 112 | Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020 , 189, e86-e90 | 4.5 | 11 |
| 111 | Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin Disease (NLPHD).. <i>Blood</i> , 2007 , 110, 644-644 | 2.2 | 11 |
| 110 | Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010 , 116, 961-961 | 2.2 | 11 |
| 109 | Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014 , 124, 4453-4453 | 2.2 | 11 |
| 108 | Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016 , 128, 2979-2979 | 2.2 | 11 |
| 107 | Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8519-8519 | 2.2 | 11 |
| 106 | Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 17-29 | 4.5 | 11 |
| 105 | Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020 , 191, 44-51 | 4.5 | 10 |
| 104 | CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.. <i>Blood Cancer Discovery</i> , 2022 , | 7 | 10 |
| 103 | A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. <i>Blood</i> , 2011 , 118, 3701-3701 | 2.2 | 10 |
| 102 | Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011 , 118, 443-443 | 2.2 | 10 |
| 101 | ACR appropriateness criteria follow-up of Hodgkin lymphoma. <i>Journal of the American College of Radiology</i> , 2014 , 11, 1026-1033.e3 | 3.5 | 9 |
| 100 | Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 1374-9 | 4 | 9 |
| 99 | Management of advanced stage Hodgkin lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 241-7 | 7.3 | 9 |
| 98 | Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016 , 128, 104-104 | 2.2 | 9 |
| 97 | Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020 , 25, 878-885 | 5.7 | 9 |
| 96 | Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. <i>Acta Haematologica</i> , 2020 , 143, 40-50 | 2.7 | 9 |
| 95 | Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 67-75 | 4 | 8 |

| | | | |
|----|---|-----|---|
| 94 | Cancer vaccines and T cell therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S97-S101 | 4.7 | 8 |
| 93 | Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015 , 126, 1540-1540 | 2.2 | 8 |
| 92 | Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. <i>Blood</i> , 2015 , 126, 2706-2706 | 2.2 | 8 |
| 91 | Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4144-4144 | 2.2 | 8 |
| 90 | Venetoclax in Previously Treated Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101194 | 2.2 | 8 |
| 89 | Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). <i>Oncotarget</i> , 2018 , 9, 766-773 | 3.3 | 8 |
| 88 | Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 1626-1626 | 2.2 | 7 |
| 87 | Phase II Study of Bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248.. <i>Blood</i> , 2005 , 106, 490-490 | 2.2 | 7 |
| 86 | Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).. <i>Blood</i> , 2011 , 118, 3711-3711 | 2.2 | 7 |
| 85 | A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. <i>Blood</i> , 2012 , 120, 2746-2746 | 2.2 | 7 |
| 84 | Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8505-8505 | 2.2 | 7 |
| 83 | Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , 2021 , 138, 213-220 | 2.2 | 7 |
| 82 | Risk-adapted therapy for advanced-stage Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 200-206 | 3.1 | 7 |
| 81 | Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 543-54 | 0.6 | 7 |
| 80 | Customized targeted therapy in Hodgkin lymphoma: hype or hope?. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 105-22 | 3.1 | 6 |
| 79 | Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. <i>Blood</i> , 2011 , 118, 3091-3091 | 2.2 | 6 |
| 78 | Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012 , 120, 60-60 | 2.2 | 6 |
| 77 | Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017 , 130, 649-649 | 2.2 | 6 |

| | | | |
|----|--|-----|---|
| 76 | Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 1648-1659 | 7.8 | 6 |
| 75 | Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2257-2265 | 2.2 | 6 |
| 74 | Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2021 , | 2.2 | 6 |
| 73 | XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. <i>Hematological Oncology</i> , 2015 , 33 Suppl 1, 90-5 | 1.3 | 5 |
| 72 | Risk stratification in extranodal natural killer/T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1395-405 | 3.5 | 5 |
| 71 | Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 4386-4386 | 2.2 | 5 |
| 70 | Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2984-2984 | 2.2 | 5 |
| 69 | Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 2993-2993 | 2.2 | 5 |
| 68 | F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2883-2893 | 8.8 | 5 |
| 67 | Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020 , 25, e993-e997 | 5.7 | 5 |
| 66 | Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018 , 132, 1635-1635 | 2.2 | 4 |
| 65 | Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018 , 132, 2899-2899 | 2.2 | 4 |
| 64 | Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2019 , 134, 468-468 | 2.2 | 4 |
| 63 | An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 655-655 | 2.2 | 4 |
| 62 | Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. <i>Blood</i> , 2014 , 124, 1745-1745 | 2.2 | 4 |
| 61 | Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. <i>Blood</i> , 2014 , 124, 3092-3092 | 2.2 | 4 |
| 60 | Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014 , 124, 629-629 | 2.2 | 4 |
| 59 | Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8506-8506 | 2.2 | 4 |

| | | | |
|----|--|-----|---|
| 58 | Novel Approaches in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 875-890 | 3.1 | 3 |
| 57 | Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin Disease (HD); the Stanford V + Radiotherapy (RT) Experience.. <i>Blood</i> , 2005 , 106, 1932-1932 | 2.2 | 3 |
| 56 | Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011 , 118, 1603-1603 | 2.2 | 3 |
| 55 | Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011 , 118, 94-94 | 2.2 | 3 |
| 54 | Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2012 , 120, 2745-2745 | 2.2 | 3 |
| 53 | Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. <i>Blood</i> , 2015 , 126, 4860-4860 | 2.2 | 3 |
| 52 | Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016 , 128, 2992-2992 | 2.2 | 3 |
| 51 | Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. <i>Blood</i> , 2017 , 130, 826-826 | 2.2 | 3 |
| 50 | Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020 , 4, e433 | 0.3 | 3 |
| 49 | Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1225-1227 | 5 | 3 |
| 48 | Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021 , 192, 542-550 | 4.5 | 3 |
| 47 | Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. <i>Journal of Oncology Practice</i> , 2017 , 13, e673-e682 | 3.1 | 2 |
| 46 | Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2018 , 132, 2937-2937 | 2.2 | 2 |
| 45 | Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , 2012 , 120, 1618-1618 | 2.2 | 2 |
| 44 | A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. <i>Blood</i> , 2013 , 122, 3044-3044 | 2.2 | 2 |
| 43 | Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013 , 122, 4277-4277 | 2.2 | 2 |
| 42 | Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e376-85 | 7.1 | 2 |
| 41 | New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 626-636 | 7.1 | 2 |

| | | | |
|----|---|-----|---|
| 40 | Bulky mediastinal classical Hodgkin lymphoma in young women. <i>Oncology</i> , 2014 , 28, 253-6, 258-60, C3 | 1.8 | 2 |
| 39 | Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 755-757 | 2.2 | 1 |
| 38 | Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. <i>Radiotherapy and Oncology</i> , 2018 , 129, 507-512 | 5.3 | 1 |
| 37 | Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018 , 132, 623-623 | 2.2 | 1 |
| 36 | A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2834-2834 | 2.2 | 1 |
| 35 | The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , 2015 , 126, 1486-1486 | 2.2 | 1 |
| 34 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. <i>Blood</i> , 2015 , 126, 1536-1536 | 2.2 | 1 |
| 33 | PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015 , 126, 176-176 | 2.2 | 1 |
| 32 | Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016 , 128, 756-756 | 2.2 | 1 |
| 31 | Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2930-2930 | 2.2 | 1 |
| 30 | Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8070-8070 | 2.2 | 1 |
| 29 | Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe | 2.2 | 1 |
| 28 | First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3006-3006 | 2.2 | 1 |
| 27 | Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 3623-3632 | 7.8 | 1 |
| 26 | Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.. <i>Oncology</i> , 2022 , 36, 51-58 | 1.8 | 0 |
| 25 | Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 878-878 | 2.2 | 0 |
| 24 | Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 4571-4571 | 2.2 | 0 |
| 23 | Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. <i>JCO Oncology Practice</i> , 2020 , 16, e902-e911 | 2.3 | 0 |

| | | | |
|----|---|-----------|---|
| 22 | Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. <i>Nuclear Medicine Communications</i> , 2021 , 42, 792-799 | 1.6 | o |
| 21 | Mycosis Fungoides and Sézary Syndrome | 2017, 1-7 | |
| 20 | PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. <i>Blood</i> , 2020 , 136, 17-18 | 2.2 | |
| 19 | Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020 , 136, 45-46 | 2.2 | |
| 18 | Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 93-93 | 2.2 | |
| 17 | Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , 2018 , 132, 2861-2861 | 2.2 | |
| 16 | A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. <i>Blood</i> , 2018 , 132, 4157-4157 | 2.2 | |
| 15 | Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2838-2838 | 2.2 | |
| 14 | Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2019 , 134, 2022-2022 | 2.2 | |
| 13 | Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. <i>Blood</i> , 2019 , 134, 4027-4027 | 2.2 | |
| 12 | North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 1553-1553 | 2.2 | |
| 11 | Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019 , 134, 4026-4026 | 2.2 | |
| 10 | Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8504-8504 | 2.2 | |
| 9 | Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8544-8544 | 2.2 | |
| 8 | Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014 , 124, 1703-1703 | 2.2 | |
| 7 | Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. <i>Blood</i> , 2015 , 126, 2702-2702 | 2.2 | |
| 6 | The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. <i>Blood</i> , 2016 , 128, 921-921 | 2.2 | |
| 5 | Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen. <i>Blood</i> , 2010 , 116, 4828-4828 | 2.2 | |

| | | |
|---|--|-----|
| 4 | Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. <i>Blood</i> , 2011 , 118, 3068-3068 | 2.2 |
| 3 | Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8060-8060 | 2.2 |
| 2 | Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. <i>Blood</i> , 2012 , 120, 4779-4779 | 2.2 |
| 1 | Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013 , 122, 643-643 | 2.2 |